Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With Hypoparathyroidism

Loading news article.

Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With Hypoparathyroidism | WAPE

Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With Hypoparathyroidism

Article summary

Related companies

Comments —